Humana
HUM
$363.86
-0.76%
Humana Inc. is a leading US managed healthcare company specializing in government-sponsored programs, with nearly all of its medical membership derived from Medicare, Medicaid, and the military's Tricare program. The company also provides complementary healthcare services, including primary care, home services, and pharmacy benefit management, positioning it as a vertically integrated player in the healthcare ecosystem. Currently, the stock is capturing investor attention due to a favorable Medicare Advantage payment rate increase from CMS, which has boosted revenue visibility and sector sentiment, while the company continues to navigate margin pressures and regulatory dynamics. Humana's strategic focus on CenterWell and integrated care delivery remains a key differentiator as it seeks to improve health outcomes and cost efficiency.…
HUM
Humana
$363.86
Related headlines
Investment Opinion: Should I buy HUM Today?
Based on the analysis, Humana is rated a Buy, supported by strong revenue growth of 23.5% YoY and a consensus analyst target of $401.30, implying 10.3% upside. The favorable Medicare payment environment and the company's strategic focus on integrated care provide a solid foundation for growth.
Sign up to view all
HUM 12-Month Price Forecast
The AI model assesses Humana as a bullish opportunity, driven by robust revenue acceleration and a supportive regulatory backdrop. However, confidence is medium due to thin margins and valuation concerns. The stance would be upgraded if margins improve or the stock pulls back to a more attractive valuation, while a downgrade would occur if revenue growth decelerates or regulatory headwinds emerge.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Humana's 12-month outlook, with a consensus price target around $407.83 and implied upside of +12.1% versus the current price.
Average Target
$407.83
0 analysts
Implied Upside
+12.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$249 - $513
Analyst target range
Humana is covered by 23 analysts, with a consensus recommendation of 'Buy' and a mean recommendation score of 2.35 (where 1 is Strong Buy and 5 is Sell). The average price target is $401.30, implying an upside of approximately 10.3% from the current price of $363.86. The distribution of ratings is not provided, but the consensus leans bullish, reflecting confidence in the company's growth prospects and the favorable Medicare payment environment.
Bulls vs Bears: HUM Investment Factors
Humana presents a compelling growth story with robust revenue acceleration and a favorable Medicare payment environment, but its razor-thin margins and elevated earnings multiples introduce significant risk. The bull case is currently stronger, supported by strong analyst conviction and sector tailwinds, yet the bear case hinges on margin sustainability and valuation compression. The most critical tension is whether Humana can convert its top-line growth into meaningful bottom-line profitability; if margins expand, the stock could re-rate higher, but any miss on cost management could trigger sharp downside.
Bullish
- Strong Revenue Growth: Q1 2026 revenue surged 23.5% YoY to $39.65B, accelerating from prior quarters, driven by premium rate increases and membership expansion in Medicare Advantage.
- Favorable Medicare Payment Environment: CMS announced a larger-than-expected 2027 Medicare Advantage payment increase, boosting revenue visibility and sector sentiment, directly benefiting Humana's core business.
- Analyst Consensus Buy with Upside: 23 analysts rate HUM a 'Buy' with an average price target of $401.30, implying ~10.3% upside from the current price of $363.86, reflecting confidence in growth prospects.
- Undervalued on Sales and EV Basis: PS ratio of 0.24x and EV/Sales of 0.24x are significantly below industry averages, suggesting the market is not fully pricing in the company's revenue scale.
Bearish
- Thin Profit Margins: Net margin is only 0.9% and operating margin 1.1%, leaving little room for error; Q4 2025 posted a net loss of $796M, showing earnings volatility.
- High Valuation on Earnings: Trailing P/E of 25.95x and forward P/E of 22.35x are elevated for a low-margin insurer, implying the market expects ~16% earnings growth that may not materialize.
- Recent Price Decline: Stock fell 11.1% in the last month and 2.8% in the last day, indicating short-term bearish momentum and potential profit-taking after a strong run.
- Regulatory and Policy Risk: Dependence on government programs (Medicare, Medicaid) exposes HUM to policy changes; any unfavorable CMS rate adjustments could pressure margins and membership.
HUM Technical Analysis
Humana's stock has exhibited a powerful uptrend over the past year, with a 1-year price change of +45.6%, significantly outperforming the S&P 500's +18.2% gain. The current price of $363.86 sits at 84.8% of its 52-week range (low: $163.11, high: $428.88), indicating the stock is trading near the upper end of its range, reflecting strong momentum and investor optimism. This positioning suggests the market is rewarding the company's recent operational improvements and the favorable Medicare payment environment, though it also raises concerns about potential overextension in the near term.
Beta
0.72
0.72x market volatility
Max Drawdown
-47.5%
Largest decline past year
52-Week Range
$163-$429
Price range past year
Annual Return
+45.6%
Cumulative gain past year
| Period | HUM Return | S&P 500 |
|---|---|---|
| 1m | -11.1% | +0.3% |
| 3m | +55.7% | +4.0% |
| 6m | +86.4% | +8.3% |
| 1y | +45.6% | +20.2% |
| ytd | +37.6% | +9.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HUM Fundamental Analysis
Humana's revenue trajectory has been robust, with the most recent quarter (Q1 2026) reporting revenue of $39.65 billion, a 23.5% year-over-year increase, accelerating from the prior year's growth rates. The company's revenue segments show Insurance contributing $38.06 billion and CenterWell $6.1 billion, with the Insurance segment driving the bulk of growth, supported by premium rate increases and membership expansion. This strong top-line growth underscores Humana's ability to capitalize on the growing Medicare Advantage market, though sustainability depends on maintaining competitive pricing and managing medical cost trends.
Quarterly Revenue
$39.6B
2026-03
Revenue YoY Growth
+23.5%
YoY Comparison
Gross Margin
15.0%
Latest Quarter
Free Cash Flow
$1.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HUM Overvalued?
Given Humana's positive net income, the trailing P/E ratio of 25.95x is the primary valuation metric, with a forward P/E of 22.35x, implying the market expects earnings growth of approximately 16% over the next year. The stock trades at a price-to-sales ratio of 0.24x, which is significantly below the industry average, reflecting the low-margin nature of the health insurance business. The EV/EBITDA multiple of 13.61x is also below the sector average, suggesting the stock is not overvalued on an enterprise basis.
PE
26.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 4x~24x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financially, Humana's profitability is fragile, with net margin of just 0.9% and operating margin of 1.1%, leaving little buffer against cost overruns. The company's debt-to-equity ratio of 0.73 and current ratio of 0.72 highlight a leveraged balance sheet and potential liquidity stress, especially if medical costs rise unexpectedly. Free cash flow of $1.27B TTM is modest relative to revenue, and the Q4 2025 net loss of $796M demonstrates earnings volatility that could recur.
FAQ
The key risks include: 1) Financial risk from thin margins (net margin 0.9%) and high debt (D/E 0.73), which could lead to earnings volatility. 2) Regulatory risk from CMS payment changes, as a rate cut could significantly impact profitability. 3) Competitive risk from rivals like UnitedHealth and CVS, who are also targeting Medicare Advantage growth. 4) Valuation risk if the stock's premium multiple contracts. The most severe risk is a regulatory change that reduces payments, potentially driving the stock down to its 52-week low of $163.11.
The 12-month forecast for HUM is moderately bullish, with a base case target of $380-$420 (50% probability), aligning with the analyst average of $401.30. The bull case targets $450-$513 (30% probability) if margins improve, while the bear case sees $250-$300 (20% probability) if costs spike. The most likely scenario is steady growth, but investors should watch margin trends and regulatory news.
Humana's valuation is mixed: on a price-to-sales basis (0.24x) and EV/Sales (0.24x), it appears undervalued relative to the industry, but on earnings (trailing P/E of 25.95x), it trades at a premium. The forward P/E of 22.35x implies the market expects ~16% earnings growth, which is optimistic given the company's thin margins. Overall, the stock is fairly valued to slightly overvalued, depending on whether the growth materializes.
Humana is a good buy for investors with a growth-oriented portfolio, given its strong revenue growth of 23.5% YoY and a consensus 'Buy' rating with 10.3% upside to the average target. However, the stock's thin margins and high valuation on earnings (forward P/E of 22.35x) introduce risk. It is best suited for those who believe the company can improve profitability and who can tolerate potential volatility. For risk-averse investors, waiting for a pullback to a lower valuation might be prudent.
Humana is better suited for long-term investment, given its growth trajectory in the Medicare Advantage market and its beta of 0.72, which indicates lower volatility than the market. The stock has shown strong 1-year performance (+45.6%), but short-term fluctuations are possible, as seen in the recent 11% monthly decline. A minimum holding period of 3-5 years is recommended to ride out regulatory and margin cycles, allowing the company's integrated care strategy to deliver value.